Compare FCF & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | IMCR |
|---|---|---|
| Founded | 1934 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | FCF | IMCR |
|---|---|---|
| Price | $17.32 | $33.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $19.50 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 669.5K | 350.2K |
| Earning Date | 01-27-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $468,728,000.00 | $379,590,000.00 |
| Revenue This Year | $17.35 | $32.42 |
| Revenue Next Year | $7.59 | $11.17 |
| P/E Ratio | $12.57 | ★ N/A |
| Revenue Growth | 2.69 | ★ 28.11 |
| 52 Week Low | $13.54 | $23.15 |
| 52 Week High | $18.28 | $40.72 |
| Indicator | FCF | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 42.18 |
| Support Level | $16.97 | $32.00 |
| Resistance Level | $17.73 | $34.71 |
| Average True Range (ATR) | 0.35 | 1.49 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 67.17 | 34.83 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.